ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Cancer Immuno Personalized Medicine Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-20O17332
Home | Market Reports | Health| Health Conditions| Cancer
Global Cancer Immuno Personalized Medicine Market Research Report 2024
BUY CHAPTERS

Global Cancer Immuno Personalized Medicine Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-20O17332
Report
October 2025
Pages:146
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol–Myers Squibb
Amgen Inc
Astrazeneca plc
Merck
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer Inc
GSK
Exelixis Inc
Regeneron
Innovent
Hengrui Medicine
Johnson & Johnson

Cancer Immuno Personalized Medicine Market

The global Cancer Immuno Personalized Medicine market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Immunotherapy is a type of medical treatment that harnesses the body's own immune system to fight diseases, particularly cancer. Unlike traditional treatments such as chemotherapy and radiation therapy, which directly target cancer cells, immunotherapy stimulates the body's natural defenses to identify and destroy cancer cells more effectively. It is a type of personalized treatment. (Immunotherapy is often tailored to the patient's specific cancer and immune system. Biomarker testing is sometimes performed to determine the suitability of certain immunotherapy drugs.)
From a downstream perspective, Lung Cancer accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Cancer Immuno Personalized Medicine leading manufacturers including AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, etc., dominate supply; the top five capture approximately % of global revenue, with AbbVie leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Cancer Immuno Personalized Medicine market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Cancer Immuno Personalized Medicine Market Report

Report Metric Details
Report Name Cancer Immuno Personalized Medicine Market
Segment by Type
  • Immune Checkpoint Inhibitors
  • Cytokine-Based Immunotherapy
  • CAR-T Cell Therapy
  • Other
Segment by Application
  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Blood-related Cancer
  • Other
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, Merck KGaA, Seagen, Eli Lilly, Ono Pharmaceutical, Pfizer, GSK, Exelixis, Regeneron, Innovent, Hengrui Medicine
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Cancer Immuno Personalized Medicine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Cancer Immuno Personalized Medicine Market report?

Ans: The main players in the Cancer Immuno Personalized Medicine Market are AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, Merck KGaA, Seagen, Eli Lilly, Ono Pharmaceutical, Pfizer, GSK, Exelixis, Regeneron, Innovent, Hengrui Medicine

What are the Application segmentation covered in the Cancer Immuno Personalized Medicine Market report?

Ans: The Applications covered in the Cancer Immuno Personalized Medicine Market report are Lung Cancer, Breast Cancer, Prostate Cancer, Blood-related Cancer, Other

What are the Type segmentation covered in the Cancer Immuno Personalized Medicine Market report?

Ans: The Types covered in the Cancer Immuno Personalized Medicine Market report are Immune Checkpoint Inhibitors, Cytokine-Based Immunotherapy, CAR-T Cell Therapy, Other

1 Study Coverage
1.1 Introduction to Cancer Immuno Personalized Medicine: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Cancer Immuno Personalized Medicine Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Cytokine-Based Immunotherapy
1.2.4 CAR-T Cell Therapy
1.2.5 Other
1.3 Market Segmentation by Application
1.3.1 Global Cancer Immuno Personalized Medicine Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Prostate Cancer
1.3.5 Blood-related Cancer
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Cancer Immuno Personalized Medicine Revenue Estimates and Forecasts 2020-2031
2.2 Global Cancer Immuno Personalized Medicine Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Cancer Immuno Personalized Medicine Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Cancer Immuno Personalized Medicine Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Immune Checkpoint Inhibitors Market Size by Players
3.3.2 Cytokine-Based Immunotherapy Market Size by Players
3.3.3 CAR-T Cell Therapy Market Size by Players
3.3.4 Other Market Size by Players
3.4 Global Cancer Immuno Personalized Medicine Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Cancer Immuno Personalized Medicine Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Cancer Immuno Personalized Medicine Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Cancer Immuno Personalized Medicine Market Size by Type (2020-2031)
6.4 North America Cancer Immuno Personalized Medicine Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Cancer Immuno Personalized Medicine Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Cancer Immuno Personalized Medicine Market Size by Type (2020-2031)
7.4 Europe Cancer Immuno Personalized Medicine Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Cancer Immuno Personalized Medicine Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Cancer Immuno Personalized Medicine Market Size by Type (2020-2031)
8.4 Asia-Pacific Cancer Immuno Personalized Medicine Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Cancer Immuno Personalized Medicine Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Cancer Immuno Personalized Medicine Market Size by Type (2020-2031)
9.4 Central and South America Cancer Immuno Personalized Medicine Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Cancer Immuno Personalized Medicine Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Cancer Immuno Personalized Medicine Market Size by Type (2020-2031)
10.4 Middle East and Africa Cancer Immuno Personalized Medicine Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Cancer Immuno Personalized Medicine Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 AbbVie
11.1.1 AbbVie Corporation Information
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Cancer Immuno Personalized Medicine Product Features and Attributes
11.1.4 AbbVie Cancer Immuno Personalized Medicine Revenue and Gross Margin (2020-2025)
11.1.5 AbbVie Cancer Immuno Personalized Medicine Revenue by Product in 2024
11.1.6 AbbVie Cancer Immuno Personalized Medicine Revenue by Application in 2024
11.1.7 AbbVie Cancer Immuno Personalized Medicine Revenue by Geographic Area in 2024
11.1.8 AbbVie Cancer Immuno Personalized Medicine SWOT Analysis
11.1.9 AbbVie Recent Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Corporation Information
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Cancer Immuno Personalized Medicine Product Features and Attributes
11.2.4 Johnson & Johnson Cancer Immuno Personalized Medicine Revenue and Gross Margin (2020-2025)
11.2.5 Johnson & Johnson Cancer Immuno Personalized Medicine Revenue by Product in 2024
11.2.6 Johnson & Johnson Cancer Immuno Personalized Medicine Revenue by Application in 2024
11.2.7 Johnson & Johnson Cancer Immuno Personalized Medicine Revenue by Geographic Area in 2024
11.2.8 Johnson & Johnson Cancer Immuno Personalized Medicine SWOT Analysis
11.2.9 Johnson & Johnson Recent Developments
11.3 Novartis
11.3.1 Novartis Corporation Information
11.3.2 Novartis Business Overview
11.3.3 Novartis Cancer Immuno Personalized Medicine Product Features and Attributes
11.3.4 Novartis Cancer Immuno Personalized Medicine Revenue and Gross Margin (2020-2025)
11.3.5 Novartis Cancer Immuno Personalized Medicine Revenue by Product in 2024
11.3.6 Novartis Cancer Immuno Personalized Medicine Revenue by Application in 2024
11.3.7 Novartis Cancer Immuno Personalized Medicine Revenue by Geographic Area in 2024
11.3.8 Novartis Cancer Immuno Personalized Medicine SWOT Analysis
11.3.9 Novartis Recent Developments
11.4 Gilead Sciences
11.4.1 Gilead Sciences Corporation Information
11.4.2 Gilead Sciences Business Overview
11.4.3 Gilead Sciences Cancer Immuno Personalized Medicine Product Features and Attributes
11.4.4 Gilead Sciences Cancer Immuno Personalized Medicine Revenue and Gross Margin (2020-2025)
11.4.5 Gilead Sciences Cancer Immuno Personalized Medicine Revenue by Product in 2024
11.4.6 Gilead Sciences Cancer Immuno Personalized Medicine Revenue by Application in 2024
11.4.7 Gilead Sciences Cancer Immuno Personalized Medicine Revenue by Geographic Area in 2024
11.4.8 Gilead Sciences Cancer Immuno Personalized Medicine SWOT Analysis
11.4.9 Gilead Sciences Recent Developments
11.5 Roche
11.5.1 Roche Corporation Information
11.5.2 Roche Business Overview
11.5.3 Roche Cancer Immuno Personalized Medicine Product Features and Attributes
11.5.4 Roche Cancer Immuno Personalized Medicine Revenue and Gross Margin (2020-2025)
11.5.5 Roche Cancer Immuno Personalized Medicine Revenue by Product in 2024
11.5.6 Roche Cancer Immuno Personalized Medicine Revenue by Application in 2024
11.5.7 Roche Cancer Immuno Personalized Medicine Revenue by Geographic Area in 2024
11.5.8 Roche Cancer Immuno Personalized Medicine SWOT Analysis
11.5.9 Roche Recent Developments
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Corporation Information
11.6.2 Bristol-Myers Squibb Business Overview
11.6.3 Bristol-Myers Squibb Cancer Immuno Personalized Medicine Product Features and Attributes
11.6.4 Bristol-Myers Squibb Cancer Immuno Personalized Medicine Revenue and Gross Margin (2020-2025)
11.6.5 Bristol-Myers Squibb Recent Developments
11.7 Amgen
11.7.1 Amgen Corporation Information
11.7.2 Amgen Business Overview
11.7.3 Amgen Cancer Immuno Personalized Medicine Product Features and Attributes
11.7.4 Amgen Cancer Immuno Personalized Medicine Revenue and Gross Margin (2020-2025)
11.7.5 Amgen Recent Developments
11.8 AstraZeneca
11.8.1 AstraZeneca Corporation Information
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Cancer Immuno Personalized Medicine Product Features and Attributes
11.8.4 AstraZeneca Cancer Immuno Personalized Medicine Revenue and Gross Margin (2020-2025)
11.8.5 AstraZeneca Recent Developments
11.9 Merck & Co
11.9.1 Merck & Co Corporation Information
11.9.2 Merck & Co Business Overview
11.9.3 Merck & Co Cancer Immuno Personalized Medicine Product Features and Attributes
11.9.4 Merck & Co Cancer Immuno Personalized Medicine Revenue and Gross Margin (2020-2025)
11.9.5 Merck & Co Recent Developments
11.10 Takeda
11.10.1 Takeda Corporation Information
11.10.2 Takeda Business Overview
11.10.3 Takeda Cancer Immuno Personalized Medicine Product Features and Attributes
11.10.4 Takeda Cancer Immuno Personalized Medicine Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Merck KGaA
11.11.1 Merck KGaA Corporation Information
11.11.2 Merck KGaA Business Overview
11.11.3 Merck KGaA Cancer Immuno Personalized Medicine Product Features and Attributes
11.11.4 Merck KGaA Cancer Immuno Personalized Medicine Revenue and Gross Margin (2020-2025)
11.11.5 Merck KGaA Recent Developments
11.12 Seagen
11.12.1 Seagen Corporation Information
11.12.2 Seagen Business Overview
11.12.3 Seagen Cancer Immuno Personalized Medicine Product Features and Attributes
11.12.4 Seagen Cancer Immuno Personalized Medicine Revenue and Gross Margin (2020-2025)
11.12.5 Seagen Recent Developments
11.13 Eli Lilly
11.13.1 Eli Lilly Corporation Information
11.13.2 Eli Lilly Business Overview
11.13.3 Eli Lilly Cancer Immuno Personalized Medicine Product Features and Attributes
11.13.4 Eli Lilly Cancer Immuno Personalized Medicine Revenue and Gross Margin (2020-2025)
11.13.5 Eli Lilly Recent Developments
11.14 Ono Pharmaceutical
11.14.1 Ono Pharmaceutical Corporation Information
11.14.2 Ono Pharmaceutical Business Overview
11.14.3 Ono Pharmaceutical Cancer Immuno Personalized Medicine Product Features and Attributes
11.14.4 Ono Pharmaceutical Cancer Immuno Personalized Medicine Revenue and Gross Margin (2020-2025)
11.14.5 Ono Pharmaceutical Recent Developments
11.15 Pfizer
11.15.1 Pfizer Corporation Information
11.15.2 Pfizer Business Overview
11.15.3 Pfizer Cancer Immuno Personalized Medicine Product Features and Attributes
11.15.4 Pfizer Cancer Immuno Personalized Medicine Revenue and Gross Margin (2020-2025)
11.15.5 Pfizer Recent Developments
11.16 GSK
11.16.1 GSK Corporation Information
11.16.2 GSK Business Overview
11.16.3 GSK Cancer Immuno Personalized Medicine Product Features and Attributes
11.16.4 GSK Cancer Immuno Personalized Medicine Revenue and Gross Margin (2020-2025)
11.16.5 GSK Recent Developments
11.17 Exelixis
11.17.1 Exelixis Corporation Information
11.17.2 Exelixis Business Overview
11.17.3 Exelixis Cancer Immuno Personalized Medicine Product Features and Attributes
11.17.4 Exelixis Cancer Immuno Personalized Medicine Revenue and Gross Margin (2020-2025)
11.17.5 Exelixis Recent Developments
11.18 Regeneron
11.18.1 Regeneron Corporation Information
11.18.2 Regeneron Business Overview
11.18.3 Regeneron Cancer Immuno Personalized Medicine Product Features and Attributes
11.18.4 Regeneron Cancer Immuno Personalized Medicine Revenue and Gross Margin (2020-2025)
11.18.5 Regeneron Recent Developments
11.19 Innovent
11.19.1 Innovent Corporation Information
11.19.2 Innovent Business Overview
11.19.3 Innovent Cancer Immuno Personalized Medicine Product Features and Attributes
11.19.4 Innovent Cancer Immuno Personalized Medicine Revenue and Gross Margin (2020-2025)
11.19.5 Innovent Recent Developments
11.20 Hengrui Medicine
11.20.1 Hengrui Medicine Corporation Information
11.20.2 Hengrui Medicine Business Overview
11.20.3 Hengrui Medicine Cancer Immuno Personalized Medicine Product Features and Attributes
11.20.4 Hengrui Medicine Cancer Immuno Personalized Medicine Revenue and Gross Margin (2020-2025)
11.20.5 Hengrui Medicine Recent Developments
12 Cancer Immuno Personalized MedicineIndustry Chain Analysis
12.1 Cancer Immuno Personalized Medicine Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Cancer Immuno Personalized Medicine Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Cancer Immuno Personalized Medicine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol–Myers Squibb
Amgen Inc
Astrazeneca plc
Merck
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer Inc
GSK
Exelixis Inc
Regeneron
Innovent
Hengrui Medicine
Johnson & Johnson
List of Tables
 Table 1. Global Cancer Immuno Personalized Medicine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Cancer Immuno Personalized Medicine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Cancer Immuno Personalized Medicine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Cancer Immuno Personalized Medicine Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Cancer Immuno Personalized Medicine Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Cancer Immuno Personalized Medicine Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Cancer Immuno Personalized Medicine Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Cancer Immuno Personalized Medicine by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Immuno Personalized Medicine as of 2024)
 Table 11. Global Cancer Immuno Personalized Medicine Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Cancer Immuno Personalized Medicine Companies Headquarters
 Table 13. Global Cancer Immuno Personalized Medicine Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Cancer Immuno Personalized Medicine Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Cancer Immuno Personalized Medicine Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Cancer Immuno Personalized Medicine Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Cancer Immuno Personalized Medicine Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Cancer Immuno Personalized Medicine High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Cancer Immuno Personalized Medicine Growth Accelerators and Market Barriers
 Table 25. North America Cancer Immuno Personalized Medicine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Cancer Immuno Personalized Medicine Growth Accelerators and Market Barriers
 Table 27. Europe Cancer Immuno Personalized Medicine Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Cancer Immuno Personalized Medicine Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Cancer Immuno Personalized Medicine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Cancer Immuno Personalized Medicine Investment Opportunities and Key Challenges
 Table 31. Central and South America Cancer Immuno Personalized Medicine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Cancer Immuno Personalized Medicine Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Cancer Immuno Personalized Medicine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. AbbVie Corporation Information
 Table 35. AbbVie Description and Major Businesses
 Table 36. AbbVie Product Features and Attributes
 Table 37. AbbVie Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. AbbVie Revenue Proportion by Product in 2024
 Table 39. AbbVie Revenue Proportion by Application in 2024
 Table 40. AbbVie Revenue Proportion by Geographic Area in 2024
 Table 41. AbbVie Cancer Immuno Personalized Medicine SWOT Analysis
 Table 42. AbbVie Recent Developments
 Table 43. Johnson & Johnson Corporation Information
 Table 44. Johnson & Johnson Description and Major Businesses
 Table 45. Johnson & Johnson Product Features and Attributes
 Table 46. Johnson & Johnson Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Johnson & Johnson Revenue Proportion by Product in 2024
 Table 48. Johnson & Johnson Revenue Proportion by Application in 2024
 Table 49. Johnson & Johnson Revenue Proportion by Geographic Area in 2024
 Table 50. Johnson & Johnson Cancer Immuno Personalized Medicine SWOT Analysis
 Table 51. Johnson & Johnson Recent Developments
 Table 52. Novartis Corporation Information
 Table 53. Novartis Description and Major Businesses
 Table 54. Novartis Product Features and Attributes
 Table 55. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Novartis Revenue Proportion by Product in 2024
 Table 57. Novartis Revenue Proportion by Application in 2024
 Table 58. Novartis Revenue Proportion by Geographic Area in 2024
 Table 59. Novartis Cancer Immuno Personalized Medicine SWOT Analysis
 Table 60. Novartis Recent Developments
 Table 61. Gilead Sciences Corporation Information
 Table 62. Gilead Sciences Description and Major Businesses
 Table 63. Gilead Sciences Product Features and Attributes
 Table 64. Gilead Sciences Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. Gilead Sciences Revenue Proportion by Product in 2024
 Table 66. Gilead Sciences Revenue Proportion by Application in 2024
 Table 67. Gilead Sciences Revenue Proportion by Geographic Area in 2024
 Table 68. Gilead Sciences Cancer Immuno Personalized Medicine SWOT Analysis
 Table 69. Gilead Sciences Recent Developments
 Table 70. Roche Corporation Information
 Table 71. Roche Description and Major Businesses
 Table 72. Roche Product Features and Attributes
 Table 73. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Roche Revenue Proportion by Product in 2024
 Table 75. Roche Revenue Proportion by Application in 2024
 Table 76. Roche Revenue Proportion by Geographic Area in 2024
 Table 77. Roche Cancer Immuno Personalized Medicine SWOT Analysis
 Table 78. Roche Recent Developments
 Table 79. Bristol-Myers Squibb Corporation Information
 Table 80. Bristol-Myers Squibb Description and Major Businesses
 Table 81. Bristol-Myers Squibb Product Features and Attributes
 Table 82. Bristol-Myers Squibb Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. Bristol-Myers Squibb Recent Developments
 Table 84. Amgen Corporation Information
 Table 85. Amgen Description and Major Businesses
 Table 86. Amgen Product Features and Attributes
 Table 87. Amgen Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Amgen Recent Developments
 Table 89. AstraZeneca Corporation Information
 Table 90. AstraZeneca Description and Major Businesses
 Table 91. AstraZeneca Product Features and Attributes
 Table 92. AstraZeneca Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. AstraZeneca Recent Developments
 Table 94. Merck & Co Corporation Information
 Table 95. Merck & Co Description and Major Businesses
 Table 96. Merck & Co Product Features and Attributes
 Table 97. Merck & Co Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 98. Merck & Co Recent Developments
 Table 99. Takeda Corporation Information
 Table 100. Takeda Description and Major Businesses
 Table 101. Takeda Product Features and Attributes
 Table 102. Takeda Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 103. Takeda Recent Developments
 Table 104. Merck KGaA Corporation Information
 Table 105. Merck KGaA Description and Major Businesses
 Table 106. Merck KGaA Product Features and Attributes
 Table 107. Merck KGaA Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 108. Merck KGaA Recent Developments
 Table 109. Seagen Corporation Information
 Table 110. Seagen Description and Major Businesses
 Table 111. Seagen Product Features and Attributes
 Table 112. Seagen Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 113. Seagen Recent Developments
 Table 114. Eli Lilly Corporation Information
 Table 115. Eli Lilly Description and Major Businesses
 Table 116. Eli Lilly Product Features and Attributes
 Table 117. Eli Lilly Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 118. Eli Lilly Recent Developments
 Table 119. Ono Pharmaceutical Corporation Information
 Table 120. Ono Pharmaceutical Description and Major Businesses
 Table 121. Ono Pharmaceutical Product Features and Attributes
 Table 122. Ono Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 123. Ono Pharmaceutical Recent Developments
 Table 124. Pfizer Corporation Information
 Table 125. Pfizer Description and Major Businesses
 Table 126. Pfizer Product Features and Attributes
 Table 127. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 128. Pfizer Recent Developments
 Table 129. GSK Corporation Information
 Table 130. GSK Description and Major Businesses
 Table 131. GSK Product Features and Attributes
 Table 132. GSK Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 133. GSK Recent Developments
 Table 134. Exelixis Corporation Information
 Table 135. Exelixis Description and Major Businesses
 Table 136. Exelixis Product Features and Attributes
 Table 137. Exelixis Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 138. Exelixis Recent Developments
 Table 139. Regeneron Corporation Information
 Table 140. Regeneron Description and Major Businesses
 Table 141. Regeneron Product Features and Attributes
 Table 142. Regeneron Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 143. Regeneron Recent Developments
 Table 144. Innovent Corporation Information
 Table 145. Innovent Description and Major Businesses
 Table 146. Innovent Product Features and Attributes
 Table 147. Innovent Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 148. Innovent Recent Developments
 Table 149. Hengrui Medicine Corporation Information
 Table 150. Hengrui Medicine Description and Major Businesses
 Table 151. Hengrui Medicine Product Features and Attributes
 Table 152. Hengrui Medicine Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 153. Hengrui Medicine Recent Developments
 Table 154. Raw Materials Key Suppliers
 Table 155. Distributors List
 Table 156. Market Trends and Market Evolution
 Table 157. Market Drivers and Opportunities
 Table 158. Market Challenges, Risks, and Restraints
 Table 159. Research Programs/Design for This Report
 Table 160. Key Data Information from Secondary Sources
 Table 161. Key Data Information from Primary Sources


List of Figures
 Figure 1. Cancer Immuno Personalized Medicine Product Picture
 Figure 2. Global Cancer Immuno Personalized Medicine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Immune Checkpoint Inhibitors Product Picture
 Figure 4. Cytokine-Based Immunotherapy Product Picture
 Figure 5. CAR-T Cell Therapy Product Picture
 Figure 6. Other Product Picture
 Figure 7. Global Cancer Immuno Personalized Medicine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 8. Lung Cancer
 Figure 9. Breast Cancer
 Figure 10. Prostate Cancer
 Figure 11. Blood-related Cancer
 Figure 12. Other
 Figure 13. Cancer Immuno Personalized Medicine Report Years Considered
 Figure 14. Global Cancer Immuno Personalized Medicine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Cancer Immuno Personalized Medicine Revenue (2020-2031) & (US$ Million)
 Figure 16. Global Cancer Immuno Personalized Medicine Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 17. Global Cancer Immuno Personalized Medicine Revenue Market Share by Region (2020-2031)
 Figure 18. Global Cancer Immuno Personalized Medicine Revenue Market Share Ranking (2024)
 Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 20. Immune Checkpoint Inhibitors Revenue Market Share by Player in 2024
 Figure 21. Cytokine-Based Immunotherapy Revenue Market Share by Player in 2024
 Figure 22. CAR-T Cell Therapy Revenue Market Share by Player in 2024
 Figure 23. Other Revenue Market Share by Player in 2024
 Figure 24. Global Cancer Immuno Personalized Medicine Revenue Market Share by Type (2020-2031)
 Figure 25. Global Cancer Immuno Personalized Medicine Revenue Market Share by Application (2020-2031)
 Figure 26. North America Cancer Immuno Personalized Medicine Revenue YoY (2020-2031) & (US$ Million)
 Figure 27. North America Top 5 Players Cancer Immuno Personalized Medicine Revenue (US$ Million) in 2024
 Figure 28. North America Cancer Immuno Personalized Medicine Revenue (US$ Million) by Type (2020 - 2031)
 Figure 29. North America Cancer Immuno Personalized Medicine Revenue (US$ Million) by Application (2020-2031)
 Figure 30. US Cancer Immuno Personalized Medicine Revenue (2020-2031) & (US$ Million)
 Figure 31. Canada Cancer Immuno Personalized Medicine Revenue (2020-2031) & (US$ Million)
 Figure 32. Mexico Cancer Immuno Personalized Medicine Revenue (2020-2031) & (US$ Million)
 Figure 33. Europe Cancer Immuno Personalized Medicine Revenue YoY (2020-2031) & (US$ Million)
 Figure 34. Europe Top 5 Players Cancer Immuno Personalized Medicine Revenue (US$ Million) in 2024
 Figure 35. Europe Cancer Immuno Personalized Medicine Revenue (US$ Million) by Type (2020-2031)
 Figure 36. Europe Cancer Immuno Personalized Medicine Revenue (US$ Million) by Application (2020-2031)
 Figure 37. Germany Cancer Immuno Personalized Medicine Revenue (2020-2031) & (US$ Million)
 Figure 38. France Cancer Immuno Personalized Medicine Revenue (2020-2031) & (US$ Million)
 Figure 39. U.K. Cancer Immuno Personalized Medicine Revenue (2020-2031) & (US$ Million)
 Figure 40. Italy Cancer Immuno Personalized Medicine Revenue (2020-2031) & (US$ Million)
 Figure 41. Russia Cancer Immuno Personalized Medicine Revenue (2020-2031) & (US$ Million)
 Figure 42. Asia-Pacific Cancer Immuno Personalized Medicine Revenue YoY (2020-2031) & (US$ Million)
 Figure 43. Asia-Pacific Top 8 Players Cancer Immuno Personalized Medicine Revenue (US$ Million) in 2024
 Figure 44. Asia-Pacific Cancer Immuno Personalized Medicine Revenue (US$ Million) by Type (2020-2031)
 Figure 45. Asia-Pacific Cancer Immuno Personalized Medicine Revenue (US$ Million) by Application (2020-2031)
 Figure 46. Indonesia Cancer Immuno Personalized Medicine Revenue (2020-2031) & (US$ Million)
 Figure 47. Japan Cancer Immuno Personalized Medicine Revenue (2020-2031) & (US$ Million)
 Figure 48. South Korea Cancer Immuno Personalized Medicine Revenue (2020-2031) & (US$ Million)
 Figure 49. Australia Cancer Immuno Personalized Medicine Revenue (2020-2031) & (US$ Million)
 Figure 50. India Cancer Immuno Personalized Medicine Revenue (2020-2031) & (US$ Million)
 Figure 51. Indonesia Cancer Immuno Personalized Medicine Revenue (2020-2031) & (US$ Million)
 Figure 52. Vietnam Cancer Immuno Personalized Medicine Revenue (2020-2031) & (US$ Million)
 Figure 53. Malaysia Cancer Immuno Personalized Medicine Revenue (2020-2031) & (US$ Million)
 Figure 54. Philippines Cancer Immuno Personalized Medicine Revenue (2020-2031) & (US$ Million)
 Figure 55. Singapore Cancer Immuno Personalized Medicine Revenue (2020-2031) & (US$ Million)
 Figure 56. Central and South America Cancer Immuno Personalized Medicine Revenue YoY (2020-2031) & (US$ Million)
 Figure 57. Central and South America Top 5 Players Cancer Immuno Personalized Medicine Revenue (US$ Million) in 2024
 Figure 58. Central and South America Cancer Immuno Personalized Medicine Revenue (US$ Million) by Type (2020-2031)
 Figure 59. Central and South America Cancer Immuno Personalized Medicine Revenue (US$ Million) by Application (2020-2031)
 Figure 60. Brazil Cancer Immuno Personalized Medicine Revenue (2020-2025) & (US$ Million)
 Figure 61. Argentina Cancer Immuno Personalized Medicine Revenue (2020-2025) & (US$ Million)
 Figure 62. Middle East and Africa Cancer Immuno Personalized Medicine Revenue YoY (2020-2031) & (US$ Million)
 Figure 63. Middle East and Africa Top 5 Players Cancer Immuno Personalized Medicine Revenue (US$ Million) in 2024
 Figure 64. South America Cancer Immuno Personalized Medicine Revenue (US$ Million) by Type (2020-2031)
 Figure 65. Middle East and Africa Cancer Immuno Personalized Medicine Revenue (US$ Million) by Application (2020-2031)
 Figure 66. GCC Countries Cancer Immuno Personalized Medicine Revenue (2020-2025) & (US$ Million)
 Figure 67. Israel Cancer Immuno Personalized Medicine Revenue (2020-2025) & (US$ Million)
 Figure 68. Egypt Cancer Immuno Personalized Medicine Revenue (2020-2025) & (US$ Million)
 Figure 69. South Africa Cancer Immuno Personalized Medicine Revenue (2020-2025) & (US$ Million)
 Figure 70. Cancer Immuno Personalized Medicine Industry Chain Mapping
 Figure 71. Channels of Distribution (Direct Vs Distribution)
 Figure 72. Bottom-up and Top-down Approaches for This Report
 Figure 73. Data Triangulation
 Figure 74. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Global Cancer Immunotherapy Drugs Market Research Report 2024
Global Cancer Immunosuppressant Treatment Market Research Report 2024
Global Immunosuppressants in Cancer Therapy Market Research Report 2024
Global Immunotherapy Drugs Market Research Report 2024
Immuno oncology Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Immunotherapeutic Drugs Market Insights Forecast to 2030
Global Immuno oncology Therapy Market Insights Forecast to 2030
Global Cancer Immunotherapy Market Insights Forecast to 2030
Global Cancer Immunotherapies Market Insights Forecast to 2030
Global Cell Immunotherapy Platform Market Research Report 2024
Global CAR T Cell Immunotherapy Market Insights Forecast to 2030
Cancer Immunotherapy Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global TCR T Cellular Immunotherapy Market Research Report 2024
Global T Cell Immunotherapy Market Research Report 2025
Global Tumor Immune Cell Therapy Market Research Report 2024
Global Immuno Oncology Service Market Research Report 2024
Oncology Immunotherapy Market
Immune Cell Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Personalized Cancer Medicine Market Research Report 2025
Global Cancer Biotherapy Market Insights Forecast to 2030

RELATED REPORTS

Global Radioactive Iodine Ablation Therapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9U20281
Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global AI Contouring Software for Radiotherapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32T20006
Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Global Cell Senescence β-Galactosidase Staining Kit Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-0Q20500
Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Global Kinase Inhibitors For Cancer Treatment Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-18V16958
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions